CoChat

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

Open access
Greco, Rita, Qu, Hongjing, Qu, Hui, Theilhaber, Joachim, Shapiro, Gary, Gregory, Richard, Winter, Christopher, Malkova, Natalia, Sun, Frank, Jaworski, Julie, Best, Annie, Pao, Lily, Hebert, Andrew, Levit, Mikhail, Protopopov, Alexei, Pollard, Jack, Bahjat, Keith, Wiederschain, Dmitri, Sharma, Sharad · 2020 · OncoImmunology
Cited by 58

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

TGFβ is a pleiotropic cytokine that may have both tumor inhibiting and tumor promoting properties, depending on tissue and cellular context. Emerging data support a role for TGFβ in suppression of antitumor immunity. Here we show that SAR439459, a pan-TGFβ neutralizing antibody, inhibits all active isoforms of human and murine TGFβ, blocks TGFβ-mediated pSMAD signaling, and TGFβ-mediated suppression of T cells and NK cells. In vitro, SAR439459 synergized with anti-PD1 to enhance T cell responsiveness. In syngeneic tumor models, SAR439459 treatment impaired tumor growth, while the combination of SAR439459 with anti–PD-1 resulted in complete tumor regression and a prolonged antitumor immunity. Mechanistically, we found that TGFβ inhibition with PD-1 blockade augmented intratumoral CD8+ T cell proliferation, reduced exhaustion, evoked proinflammatory cytokines, and promoted tumor-specific CD8+ T cell responses. Together, these data support the hypothesis that TGFβ neutralization using SAR439459 synergizes with PD-1 blockade to promote antitumor immunity and formed the basis for the ongoing clinical investigation of SAR439459 in patients with cancer (NCT03192345).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1811605

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 58

Metadata

Authors
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R., Winter, C., Malkova, N., Sun, F., Jaworski, J., Best, A., Pao, L., Hebert, A., Levit, M., Protopopov, A., Pollard, J., Bahjat, K., Wiederschain, D., & Sharma, S.
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1811605-1811605
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3085147748
Cited by
58
References
27
FWCI
2.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. https://app.cochat.ai/papers/10.1080/2162402x.2020.1811605
The paper
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R., Winter, C., Malkova, N., Sun, F., Jaworski, J., Best, A., Pao, L., Hebert, A., Levit, M., Protopopov, A., Pollard, J., Bahjat, K., Wiederschain, D., & Sharma, S. (2020). Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1811605

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.